Oryzon Genomics SA ( (ES:ORY) ) has issued an update.
Oryzon Genomics SA has announced a capital increase of 25 million euros through an accelerated private placement to institutional investors. The funds will be used to advance clinical development in CNS diseases and oncology, prepare for Phase IIb-III trials, and strengthen its financial position for potential partnerships or Nasdaq listing.
More about Oryzon Genomics SA
Oryzon Genomics SA operates in the biotechnology industry, focusing on the development of therapeutic solutions for central nervous system diseases and oncology. The company is engaged in clinical development and drug manufacturing, with a market focus on expanding its clinical trials and potential Nasdaq listing.
YTD Price Performance: 79.67%
Average Trading Volume: 2,671
Technical Sentiment Signal: Sell
Current Market Cap: €190.9M
See more data about ORY stock on TipRanks’ Stock Analysis page.